Description

BSE lists 23,06,372 new equity shares of Eris Lifesciences Limited on preferential basis, effective March 10, 2026, with lock-in until February 14, 2029.

Summary

BSE has notified trading members that 23,06,372 new equity shares of Eris Lifesciences Limited (Scrip Code: 540596) are listed and permitted to trade on the Exchange with effect from Tuesday, March 10, 2026. The shares were issued on a preferential basis to Non-Promoters at an issue price of Rs. 1,835.35/- per share and are subject to a lock-in period until February 14, 2029.

Key Points

  • 23,06,372 equity shares of face value Rs. 1/- each issued at a premium of Rs. 1,834.35/- per share
  • Issued to Non-Promoters on a preferential basis
  • Issue price: Rs. 1,835.35/- per share
  • Shares rank pari-passu with existing equity shares of the company
  • ISIN: INE406M01024
  • Distribution Numbers: 137956022 to 140262393
  • Date of Allotment: January 16, 2026

Regulatory Changes

No new regulatory changes introduced. This is a standard listing notification pursuant to preferential allotment under applicable SEBI and BSE regulations.

Compliance Requirements

  • Trading members are informed of the new securities and permitted to trade them from March 10, 2026
  • Lock-in compliance: All 23,06,372 shares (Dist. Nos. 137956022 to 140262393) are locked in until February 14, 2029 and cannot be traded during this period

Important Dates

  • Date of Allotment: January 16, 2026
  • Listing/Trading Effective Date: March 10, 2026
  • Lock-in Expiry Date: February 14, 2029

Impact Assessment

The listing of approximately 23 lakh new equity shares on a preferential basis represents a modest dilution for existing shareholders of Eris Lifesciences. The shares are locked in until February 2029, limiting near-term selling pressure from these allottees. The issue price of Rs. 1,835.35/- per share provides a reference point for market valuation. Overall market impact is moderate and limited to shareholders and analysts tracking the company’s capital structure.

Impact Justification

Routine preferential allotment listing for Eris Lifesciences with a significant lock-in period; relevant to existing shareholders and traders tracking dilution.